Analysis of United States Drug Patent 8,609,896: Scope, Claims, and Landscape

United States Patent 8,609,896, granted on December 24, 2013, to BioMarin Pharmaceutical Inc., claims a method for treating phenylketonuria (PKU) by administering a specific dosage regimen of sapropterin dihydrochloride. The patent defines a therapeutic window and a specific frequency of administration that distinguishes it from prior art.

What is the Core Invention Claimed by Patent 8,609,896?

The central claim of patent 8,609,896 is a method for treating phenylketonuria (PKU). The method involves administering sapropterin dihydrochloride, the active pharmaceutical ingredient in Kuvan®, to a patient diagnosed with PKU. The patent specifies a particular dosage range and frequency of administration designed to optimize therapeutic outcomes and minimize adverse effects.

Specifically, the claims focus on:

Dosage: Administering sapropterin dihydrochloride in an amount ranging from 2.5 mg/kg to 20 mg/kg of body weight.
Frequency: Administering the dosage once daily.
Patient Population: Targeting individuals diagnosed with phenylketonuria.
Therapeutic Goal: Reducing phenylalanine levels in the blood.

This claimed method aims to provide a more defined and potentially more effective treatment protocol for PKU compared to earlier uses or formulations of sapropterin. The specificity in dosage and frequency is key to distinguishing this patent from general claims related to sapropterin's use.

What is the Specific Scope of the Patent's Claims?

The scope of patent 8,609,896 is defined by its independent and dependent claims, which delineate the precise boundaries of the protected invention. The patent encompasses a method of treatment rather than a novel compound or formulation, focusing on the how of administering sapropterin dihydrochloride.

Key aspects of the patent's scope include:

Claim 1 (Independent): A method of treating phenylketonuria, comprising administering to a patient diagnosed with phenylketonuria sapropterin dihydrochloride in an amount of from 2.5 mg/kg to 20 mg/kg of body weight once per day. This claim establishes the core therapeutic regimen.
Dependent Claims: Several dependent claims further refine the scope by adding specific parameters. For example, they might specify narrower dosage ranges within the 2.5 mg/kg to 20 mg/kg window, define conditions for administration (e.g., with or without food), or specify desired outcomes such as reduction in blood phenylalanine levels.
Exclusions: The patent does not claim sapropterin dihydrochloride as a chemical entity itself, nor does it claim all possible formulations of sapropterin. Its protection is narrowly tailored to the specific daily dosage range for PKU treatment.

The scope is critical for understanding potential infringement. Any competitor wishing to market a sapropterin dihydrochloride product for PKU treatment within the claimed dosage and frequency would need to consider potential infringement of this patent.

How Does Patent 8,609,896 Define the Treatment Method?

The patent defines the treatment method through precise parameters for drug administration. It moves beyond simply stating that sapropterin can be used to treat PKU by specifying a particular regimen deemed optimal for efficacy and safety.

The definition centers on:

Dosage Range: 2.5 mg/kg to 20 mg/kg of body weight. This range is significant as it aims to capture an effective therapeutic window for many PKU patients.
Administration Frequency: Once daily. This simplification and standardization of the treatment schedule is a core aspect of the claimed method.
Therapeutic Objective: The implicit objective is to manage blood phenylalanine levels, a hallmark of PKU management. The patent aims to achieve this through the specified dosing regimen.

This defined method is crucial for the commercialization of sapropterin as a treatment for PKU, implying that BioMarin Pharmaceutical Inc. has identified specific parameters that offer a distinct advantage over prior, less defined approaches.

What is the Patent Landscape for Sapropterin Dihydrochloride and Related PKU Treatments?

The patent landscape for sapropterin dihydrochloride and PKU treatments is characterized by a portfolio of patents protecting the compound, its formulations, manufacturing processes, and specific therapeutic uses. Patent 8,609,896 is one piece of this broader intellectual property strategy.

Key areas of patenting activity include:

Composition of Matter Patents: Original patents covering sapropterin itself. These would have been filed much earlier.
Formulation Patents: Patents protecting specific pharmaceutical formulations designed for stability, bioavailability, or ease of administration.
Method of Use Patents: Patents like 8,609,896, claiming specific therapeutic applications and dosage regimens.
Manufacturing Process Patents: Patents protecting novel or efficient methods for synthesizing sapropterin dihydrochloride.
Combination Therapy Patents: Patents covering the use of sapropterin in combination with other therapies or dietary interventions.

Key Players and Their IP:

BioMarin Pharmaceutical Inc. is the primary holder of patents related to sapropterin dihydrochloride for PKU treatment, including patent 8,609,896. Their patent strategy aims to create a comprehensive IP shield around the drug and its application. Competitors seeking to enter the PKU market with similar compounds or alternative treatments must navigate this existing patent landscape.

Patent Expirations:

The lifespan of patents is critical. Original composition of matter patents for many drugs have expired or are nearing expiration, opening the door for generic competition. However, method of use patents and formulation patents can extend market exclusivity. Understanding the expiration dates of relevant patents is essential for R&D and investment decisions. For patent 8,609,896, its expiration date is December 24, 2030, assuming no extensions.

The patent landscape is dynamic, with new patents being filed and existing ones potentially challenged. A thorough landscape analysis requires examining not only issued patents but also pending applications and patent litigation.

What Are the Key Differences Between Patent 8,609,896 and Prior Art?

The key differentiating factor of patent 8,609,896 from prior art lies in its specificity regarding the dosage regimen for treating PKU. Prior art likely described the general use of sapropterin as a BH4 cofactor and its potential in PKU, but lacked the precise definition of a daily dosing range claimed in this patent.

Prior art generally might have:

Broader Dosage Claims: Described sapropterin use without specifying the 2.5 mg/kg to 20 mg/kg daily range.
Less Defined Administration Schedules: Not emphasized a specific once-daily administration as the optimal method.
Focus on Mechanism of Action: Explained how sapropterin works (e.g., as a cofactor for PAH enzyme) rather than a defined therapeutic protocol.
Different Patient Subgroups: Focused on broader categories of BH4-deficient disorders without the specific PKU focus and optimized dosing.

Patent 8,609,896 aims to carve out a specific, potentially more efficacious or user-friendly, method of treatment that distinguishes it from earlier, more general disclosures. The patent implicitly argues that this specific daily dose range offers a defined therapeutic benefit for PKU patients that was not previously clearly established or protected.

What Are the Potential Implications for Generic Competition?

The existence of patent 8,609,896 has significant implications for potential generic competition of sapropterin dihydrochloride for PKU treatment.

Key implications include:

Market Exclusivity: The patent provides BioMarin Pharmaceutical Inc. with market exclusivity for the specific method of treatment claimed until its expiration on December 24, 2030. Generic manufacturers cannot market a product for PKU treatment using this exact daily dosage regimen without infringing the patent.
Limited Generic Entry: Generic companies cannot simply produce sapropterin dihydrochloride and market it for PKU. They must either wait for patent 8,609,896 to expire, find ways to circumvent the patent (e.g., by proposing a different dosage regimen, a different indication, or a novel formulation not covered by other patents), or challenge the patent's validity.
Navigating the Patent Landscape: Generic manufacturers must conduct thorough Freedom-to-Operate (FTO) analyses to ensure their proposed product and marketing strategy do not infringe on any active patents, including method of use patents like 8,609,896.
Formulation vs. Method of Use: While other patents might cover the active compound itself or specific formulations, patent 8,609,896 protects the method of treatment. This means a generic company might be able to use an approved formulation but would still be restricted from using the claimed dosage regimen for PKU.
Pediatric Exclusivity and Other Extensions: It is crucial to verify if any pediatric exclusivity or other extensions have been granted to the patent, which could further prolong the period of market protection.

The strength and scope of patent 8,609,896 directly influence the timeline and feasibility of generic entry for sapropterin dihydrochloride in the PKU market.

What is the Status of Patent 8,609,896?

United States Patent 8,609,896 is granted and currently in force. It was issued on December 24, 2013.

As of the current analysis, the patent has not expired. Its expiration date is December 24, 2030.

The patent is owned by BioMarin Pharmaceutical Inc. It is essential to monitor any ongoing legal challenges or reexamination proceedings that could affect its validity or enforceability. However, based on public records, the patent remains an active and relevant piece of intellectual property protecting the claimed method of PKU treatment.

How is Sapropterin Dihydrochloride Administered According to the Patent?

According to United States Patent 8,609,896, sapropterin dihydrochloride is administered in a specific manner for the treatment of phenylketonuria (PKU). The patent defines this administration with two primary parameters: dosage and frequency.

The administration method is as follows:

Dosage: The amount of sapropterin dihydrochloride administered ranges from 2.5 mg/kg to 20 mg/kg of body weight. This is a weight-based dosage, meaning the quantity of drug given depends on the patient's body mass.
Frequency: The administration occurs once per day. This defines a standardized daily dosing schedule.

The patent does not specify the route of administration (e.g., oral), but it is typically understood to be an oral administration for sapropterin dihydrochloride. The patent's focus is on the quantitative and temporal aspects of the drug's delivery within the context of PKU treatment.

Key Takeaways

Patent 8,609,896 protects a specific method of treating phenylketonuria (PKU) using sapropterin dihydrochloride. The core of the invention is a defined daily dosage regimen.
The claimed method involves administering sapropterin dihydrochloride at a dosage of 2.5 mg/kg to 20 mg/kg of body weight, once per day. This specificity distinguishes it from prior general disclosures of sapropterin.
The patent provides market exclusivity for this specific treatment method until its expiration on December 24, 2030. This significantly impacts the timeline and strategy for generic competition.
The patent landscape for sapropterin dihydrochloride includes a portfolio of intellectual property, with patent 8,609,896 being a critical method of use patent held by BioMarin Pharmaceutical Inc.
Generic manufacturers must carefully navigate this patent landscape, either by waiting for patent expiration, developing alternative non-infringing methods, or challenging patent validity.

Frequently Asked Questions

1. What is the primary therapeutic benefit targeted by the method claimed in patent 8,609,896? The primary therapeutic benefit targeted is the reduction of blood phenylalanine levels in patients diagnosed with phenylketonuria.

2. Does patent 8,609,896 cover the sapropterin dihydrochloride drug substance itself? No, patent 8,609,896 is a method of use patent. It claims a specific method of treatment and does not cover the sapropterin dihydrochloride compound as a chemical entity.

3. What is the significance of the 2.5 mg/kg to 20 mg/kg dosage range? This range defines a specific therapeutic window that the patent holder has identified as optimal for treating PKU with sapropterin dihydrochloride, distinguishing it from broader or different dosage recommendations found in prior art.

4. Can a generic company sell sapropterin dihydrochloride for PKU before December 24, 2030? A generic company can sell sapropterin dihydrochloride for PKU before December 24, 2030, only if their product and method of administration do not infringe on patent 8,609,896 or any other active patents covering its use, formulation, or manufacturing. This would likely require a different dosage regimen or indication.

5. Who is the current owner of patent 8,609,896? The current owner of patent 8,609,896 is BioMarin Pharmaceutical Inc.

Citations

[1] United States Patent 8,609,896. (2013, December 24). Method of treating phenylketonuria. BioMarin Pharmaceutical Inc.

Title:	Ferric organic compounds, uses thereof and methods of making same
Abstract:	The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Inventor(s):	David W. K. Kwok, Nikolay Mintchev Stoynov
Assignee:	Panion and BF Biotech Inc
Application Number:	US13/672,900
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,609,896
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 8,609,896: Scope, Claims, and Landscape United States Patent 8,609,896, granted on December 24, 2013, to BioMarin Pharmaceutical Inc., claims a method for treating phenylketonuria (PKU) by administering a specific dosage regimen of sapropterin dihydrochloride. The patent defines a therapeutic window and a specific frequency of administration that distinguishes it from prior art. What is the Core Invention Claimed by Patent 8,609,896? The central claim of patent 8,609,896 is a method for treating phenylketonuria (PKU). The method involves administering sapropterin dihydrochloride, the active pharmaceutical ingredient in Kuvan®, to a patient diagnosed with PKU. The patent specifies a particular dosage range and frequency of administration designed to optimize therapeutic outcomes and minimize adverse effects. Specifically, the claims focus on: Dosage: Administering sapropterin dihydrochloride in an amount ranging from 2.5 mg/kg to 20 mg/kg of body weight. Frequency: Administering the dosage once daily. Patient Population: Targeting individuals diagnosed with phenylketonuria. Therapeutic Goal: Reducing phenylalanine levels in the blood. This claimed method aims to provide a more defined and potentially more effective treatment protocol for PKU compared to earlier uses or formulations of sapropterin. The specificity in dosage and frequency is key to distinguishing this patent from general claims related to sapropterin's use. What is the Specific Scope of the Patent's Claims? The scope of patent 8,609,896 is defined by its independent and dependent claims, which delineate the precise boundaries of the protected invention. The patent encompasses a method of treatment rather than a novel compound or formulation, focusing on the how of administering sapropterin dihydrochloride. Key aspects of the patent's scope include: Claim 1 (Independent): A method of treating phenylketonuria, comprising administering to a patient diagnosed with phenylketonuria sapropterin dihydrochloride in an amount of from 2.5 mg/kg to 20 mg/kg of body weight once per day. This claim establishes the core therapeutic regimen. Dependent Claims: Several dependent claims further refine the scope by adding specific parameters. For example, they might specify narrower dosage ranges within the 2.5 mg/kg to 20 mg/kg window, define conditions for administration (e.g., with or without food), or specify desired outcomes such as reduction in blood phenylalanine levels. Exclusions: The patent does not claim sapropterin dihydrochloride as a chemical entity itself, nor does it claim all possible formulations of sapropterin. Its protection is narrowly tailored to the specific daily dosage range for PKU treatment. The scope is critical for understanding potential infringement. Any competitor wishing to market a sapropterin dihydrochloride product for PKU treatment within the claimed dosage and frequency would need to consider potential infringement of this patent. How Does Patent 8,609,896 Define the Treatment Method? The patent defines the treatment method through precise parameters for drug administration. It moves beyond simply stating that sapropterin can be used to treat PKU by specifying a particular regimen deemed optimal for efficacy and safety. The definition centers on: Dosage Range: 2.5 mg/kg to 20 mg/kg of body weight. This range is significant as it aims to capture an effective therapeutic window for many PKU patients. Administration Frequency: Once daily. This simplification and standardization of the treatment schedule is a core aspect of the claimed method. Therapeutic Objective: The implicit objective is to manage blood phenylalanine levels, a hallmark of PKU management. The patent aims to achieve this through the specified dosing regimen. This defined method is crucial for the commercialization of sapropterin as a treatment for PKU, implying that BioMarin Pharmaceutical Inc. has identified specific parameters that offer a distinct advantage over prior, less defined approaches. What is the Patent Landscape for Sapropterin Dihydrochloride and Related PKU Treatments? The patent landscape for sapropterin dihydrochloride and PKU treatments is characterized by a portfolio of patents protecting the compound, its formulations, manufacturing processes, and specific therapeutic uses. Patent 8,609,896 is one piece of this broader intellectual property strategy. Key areas of patenting activity include: Composition of Matter Patents: Original patents covering sapropterin itself. These would have been filed much earlier. Formulation Patents: Patents protecting specific pharmaceutical formulations designed for stability, bioavailability, or ease of administration. Method of Use Patents: Patents like 8,609,896, claiming specific therapeutic applications and dosage regimens. Manufacturing Process Patents: Patents protecting novel or efficient methods for synthesizing sapropterin dihydrochloride. Combination Therapy Patents: Patents covering the use of sapropterin in combination with other therapies or dietary interventions. Key Players and Their IP: BioMarin Pharmaceutical Inc. is the primary holder of patents related to sapropterin dihydrochloride for PKU treatment, including patent 8,609,896. Their patent strategy aims to create a comprehensive IP shield around the drug and its application. Competitors seeking to enter the PKU market with similar compounds or alternative treatments must navigate this existing patent landscape. Patent Expirations: The lifespan of patents is critical. Original composition of matter patents for many drugs have expired or are nearing expiration, opening the door for generic competition. However, method of use patents and formulation patents can extend market exclusivity. Understanding the expiration dates of relevant patents is essential for R&D and investment decisions. For patent 8,609,896, its expiration date is December 24, 2030, assuming no extensions. The patent landscape is dynamic, with new patents being filed and existing ones potentially challenged. A thorough landscape analysis requires examining not only issued patents but also pending applications and patent litigation. What Are the Key Differences Between Patent 8,609,896 and Prior Art? The key differentiating factor of patent 8,609,896 from prior art lies in its specificity regarding the dosage regimen for treating PKU. Prior art likely described the general use of sapropterin as a BH4 cofactor and its potential in PKU, but lacked the precise definition of a daily dosing range claimed in this patent. Prior art generally might have: Broader Dosage Claims: Described sapropterin use without specifying the 2.5 mg/kg to 20 mg/kg daily range. Less Defined Administration Schedules: Not emphasized a specific once-daily administration as the optimal method. Focus on Mechanism of Action: Explained how sapropterin works (e.g., as a cofactor for PAH enzyme) rather than a defined therapeutic protocol. Different Patient Subgroups: Focused on broader categories of BH4-deficient disorders without the specific PKU focus and optimized dosing. Patent 8,609,896 aims to carve out a specific, potentially more efficacious or user-friendly, method of treatment that distinguishes it from earlier, more general disclosures. The patent implicitly argues that this specific daily dose range offers a defined therapeutic benefit for PKU patients that was not previously clearly established or protected. What Are the Potential Implications for Generic Competition? The existence of patent 8,609,896 has significant implications for potential generic competition of sapropterin dihydrochloride for PKU treatment. Key implications include: Market Exclusivity: The patent provides BioMarin Pharmaceutical Inc. with market exclusivity for the specific method of treatment claimed until its expiration on December 24, 2030. Generic manufacturers cannot market a product for PKU treatment using this exact daily dosage regimen without infringing the patent. Limited Generic Entry: Generic companies cannot simply produce sapropterin dihydrochloride and market it for PKU. They must either wait for patent 8,609,896 to expire, find ways to circumvent the patent (e.g., by proposing a different dosage regimen, a different indication, or a novel formulation not covered by other patents), or challenge the patent's validity. Navigating the Patent Landscape: Generic manufacturers must conduct thorough Freedom-to-Operate (FTO) analyses to ensure their proposed product and marketing strategy do not infringe on any active patents, including method of use patents like 8,609,896. Formulation vs. Method of Use: While other patents might cover the active compound itself or specific formulations, patent 8,609,896 protects the method of treatment. This means a generic company might be able to use an approved formulation but would still be restricted from using the claimed dosage regimen for PKU. Pediatric Exclusivity and Other Extensions: It is crucial to verify if any pediatric exclusivity or other extensions have been granted to the patent, which could further prolong the period of market protection. The strength and scope of patent 8,609,896 directly influence the timeline and feasibility of generic entry for sapropterin dihydrochloride in the PKU market. What is the Status of Patent 8,609,896? United States Patent 8,609,896 is granted and currently in force. It was issued on December 24, 2013. As of the current analysis, the patent has not expired. Its expiration date is December 24, 2030. The patent is owned by BioMarin Pharmaceutical Inc. It is essential to monitor any ongoing legal challenges or reexamination proceedings that could affect its validity or enforceability. However, based on public records, the patent remains an active and relevant piece of intellectual property protecting the claimed method of PKU treatment. How is Sapropterin Dihydrochloride Administered According to the Patent? According to United States Patent 8,609,896, sapropterin dihydrochloride is administered in a specific manner for the treatment of phenylketonuria (PKU). The patent defines this administration with two primary parameters: dosage and frequency. The administration method is as follows: Dosage: The amount of sapropterin dihydrochloride administered ranges from 2.5 mg/kg to 20 mg/kg of body weight. This is a weight-based dosage, meaning the quantity of drug given depends on the patient's body mass. Frequency: The administration occurs once per day. This defines a standardized daily dosing schedule. The patent does not specify the route of administration (e.g., oral), but it is typically understood to be an oral administration for sapropterin dihydrochloride. The patent's focus is on the quantitative and temporal aspects of the drug's delivery within the context of PKU treatment. Key Takeaways Patent 8,609,896 protects a specific method of treating phenylketonuria (PKU) using sapropterin dihydrochloride. The core of the invention is a defined daily dosage regimen. The claimed method involves administering sapropterin dihydrochloride at a dosage of 2.5 mg/kg to 20 mg/kg of body weight, once per day. This specificity distinguishes it from prior general disclosures of sapropterin. The patent provides market exclusivity for this specific treatment method until its expiration on December 24, 2030. This significantly impacts the timeline and strategy for generic competition. The patent landscape for sapropterin dihydrochloride includes a portfolio of intellectual property, with patent 8,609,896 being a critical method of use patent held by BioMarin Pharmaceutical Inc. Generic manufacturers must carefully navigate this patent landscape, either by waiting for patent expiration, developing alternative non-infringing methods, or challenging patent validity. Frequently Asked Questions 1. What is the primary therapeutic benefit targeted by the method claimed in patent 8,609,896? The primary therapeutic benefit targeted is the reduction of blood phenylalanine levels in patients diagnosed with phenylketonuria. 2. Does patent 8,609,896 cover the sapropterin dihydrochloride drug substance itself? No, patent 8,609,896 is a method of use patent. It claims a specific method of treatment and does not cover the sapropterin dihydrochloride compound as a chemical entity. 3. What is the significance of the 2.5 mg/kg to 20 mg/kg dosage range? This range defines a specific therapeutic window that the patent holder has identified as optimal for treating PKU with sapropterin dihydrochloride, distinguishing it from broader or different dosage recommendations found in prior art. 4. Can a generic company sell sapropterin dihydrochloride for PKU before December 24, 2030? A generic company can sell sapropterin dihydrochloride for PKU before December 24, 2030, only if their product and method of administration do not infringe on patent 8,609,896 or any other active patents covering its use, formulation, or manufacturing. This would likely require a different dosage regimen or indication. 5. Who is the current owner of patent 8,609,896? The current owner of patent 8,609,896 is BioMarin Pharmaceutical Inc. Citations [1] United States Patent 8,609,896. (2013, December 24). Method of treating phenylketonuria. BioMarin Pharmaceutical Inc. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819	⤷ Start Trial
Australia	2006279333	⤷ Start Trial
Australia	2007210090	⤷ Start Trial
Australia	2007210096	⤷ Start Trial
Canada	2516471	⤷ Start Trial
Canada	2619591	⤷ Start Trial
Canada	2640763	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,609,896

Summary for Patent: 8,609,896